Canada markets close in 2 hours 54 minutes

Celldex Therapeutics, Inc. (CLDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
44.95+1.25 (+2.86%)
As of 12:59PM EDT. Market open.
Currency in USD

Valuation Measures

Market Cap (intraday) 52.09B
Enterprise Value 31.56B
Trailing P/E N/A
Forward P/E 1-28.09
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)388.53
Price/Book (mrq)9.17
Enterprise Value/Revenue 3290.27
Enterprise Value/EBITDA 7-31.48

Trading Information

Stock Price History

Beta (5Y Monthly) 3.06
52-Week Change 3290.88%
S&P500 52-Week Change 332.68%
52 Week High 346.42
52 Week Low 39.66
50-Day Moving Average 336.54
200-Day Moving Average 328.12

Share Statistics

Avg Vol (3 month) 3825.48k
Avg Vol (10 day) 3589.97k
Shares Outstanding 546.46M
Implied Shares Outstanding 6N/A
Float 33.21M
% Held by Insiders 14.48%
% Held by Institutions 176.17%
Shares Short (Jul. 14, 2021) 43.35M
Short Ratio (Jul. 14, 2021) 42.24
Short % of Float (Jul. 14, 2021) 48.50%
Short % of Shares Outstanding (Jul. 14, 2021) 48.46%
Shares Short (prior month Jun. 14, 2021) 42.53M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Feb. 10, 2019
Ex-Dividend Date 4N/A
Last Split Factor 21:15
Last Split Date 3Feb. 10, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2020
Most Recent Quarter (mrq)Mar. 30, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-987.81%

Management Effectiveness

Return on Assets (ttm)-20.02%
Return on Equity (ttm)-45.84%

Income Statement

Revenue (ttm)5.38M
Revenue Per Share (ttm)0.15
Quarterly Revenue Growth (yoy)-74.90%
Gross Profit (ttm)-35.12M
EBITDA -49.56M
Net Income Avi to Common (ttm)-63.69M
Diluted EPS (ttm)-1.81
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)176.08M
Total Cash Per Share (mrq)4.45
Total Debt (mrq)3.14M
Total Debt/Equity (mrq)1.62
Current Ratio (mrq)10.69
Book Value Per Share (mrq)4.90

Cash Flow Statement

Operating Cash Flow (ttm)-46.38M
Levered Free Cash Flow (ttm)-23.89M